Clinical Trial Update: Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial of AD-PluReceptor plus tafasitamab-cxix with lymphodepleting chemotherapy in autoimmune disorders is currently recruiting, including systemic s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus
• Systemic Sclerosis

Drugs mentioned

• AD-PluReceptor
• Tafasitamab-cxix (tafasitamab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Autoimmune Disorders, Systemic Sclerosis | Phase 1, Phase 2 | Status: RECRUITING